Asha Therapeutics LLC
Asha Therapeutics is a biopharmaceutical company focused on developing disease-modifying and curative therapeutics for neurodegenerative, neurological, and infectious diseases with high unmet medical need. Leveraging its proprietary PRISM™ technology, the company designs de novo compounds targeting difficult-to-drug disease targets, aiming to transform patient outcomes with innovative medicines.
Industries
Nr. of Employees
small (1-50)
Products
SARM1 inhibitor (intramolecular glue) — development candidate
A first-in-class intramolecular glue small molecule designed to stabilize SARM1 in an inactive conformation to prevent axonal degeneration; demonstrated robust preclinical neuroprotection in animal models and being advanced as IND-enabling candidate for ALS, chemotherapy-induced peripheral neuropathy, retinal and other neurodegenerative indications.
DRP1 inhibitor — brain-penetrant mitochondrial dynamics modulator
A selective, brain-penetrant small molecule designed to modulate mitochondrial fission/fusion dynamics (DRP1 inhibition) to restore mitochondrial homeostasis and limit neurodegeneration; shown efficacious in preclinical models of Alzheimer's and Parkinson's disease and advanced as an IND-enabling candidate.
E3 ligase recruiter chemistry for targeted protein degradation
Small-molecule recruiter chemistry optimized for the VHL E3 ligase to enable targeted protein degradation approaches with improved pharmacokinetic and drug-like properties.
SARM1 inhibitor (intramolecular glue) — development candidate
A first-in-class intramolecular glue small molecule designed to stabilize SARM1 in an inactive conformation to prevent axonal degeneration; demonstrated robust preclinical neuroprotection in animal models and being advanced as IND-enabling candidate for ALS, chemotherapy-induced peripheral neuropathy, retinal and other neurodegenerative indications.
DRP1 inhibitor — brain-penetrant mitochondrial dynamics modulator
A selective, brain-penetrant small molecule designed to modulate mitochondrial fission/fusion dynamics (DRP1 inhibition) to restore mitochondrial homeostasis and limit neurodegeneration; shown efficacious in preclinical models of Alzheimer's and Parkinson's disease and advanced as an IND-enabling candidate.
E3 ligase recruiter chemistry for targeted protein degradation
Small-molecule recruiter chemistry optimized for the VHL E3 ligase to enable targeted protein degradation approaches with improved pharmacokinetic and drug-like properties.
Services
Partnership access to a physics-based molecular design platform for target assessment, de novo compound design, and chemistry optimization to accelerate candidate generation and reduce screening needs.
Collaborative preclinical programs including testing in patient-derived cells and animal models, study design support, and IND-enabling research for neurological and rare diseases.
Partnership access to a physics-based molecular design platform for target assessment, de novo compound design, and chemistry optimization to accelerate candidate generation and reduce screening needs.
Collaborative preclinical programs including testing in patient-derived cells and animal models, study design support, and IND-enabling research for neurological and rare diseases.
Expertise Areas
- Computational drug design
- Small-molecule medicinal chemistry
- Neurodegenerative disease therapeutics development
- Targeted protein degradation (TPD)
Key Technologies
- Physics-based molecular simulation
- De novo small-molecule design
- Intramolecular glue modality
- E3 ligase recruiter chemistry for TPD
News & Updates
CMT Research Foundation has invested in a research project with Asha to evaluate the therapeutic potential of inhibiting SARM1 using their novel drug, ASHA-624, for Charcot-Marie-Tooth disease type 2A.
Advancium's funding supports studies on ASHA-624, a SARM1 inhibitor, in a rare eye disease, aiming to evaluate its effectiveness in protecting vision.
Asha received a grant from the ALS Association to develop ASHA-624 for ALS and announced the appointment of founders from Disarm Therapeutics to its Scientific Advisory Board.
Asha nominated ASHA-624, a novel intra-molecular glue targeting SARM1, as a potential disease-modifying therapy for ALS.
Asha's CSO Dr. Bradlee Heckmann will present efficacy data for ASHA-091 at the AD/PD 2024 conference, with plans to enter clinical trials in late 2024.
CMT Research Foundation has invested in a research project with Asha to evaluate the therapeutic potential of inhibiting SARM1 using their novel drug, ASHA-624, for Charcot-Marie-Tooth disease type 2A.
Advancium's funding supports studies on ASHA-624, a SARM1 inhibitor, in a rare eye disease, aiming to evaluate its effectiveness in protecting vision.
Asha received a grant from the ALS Association to develop ASHA-624 for ALS and announced the appointment of founders from Disarm Therapeutics to its Scientific Advisory Board.
Asha nominated ASHA-624, a novel intra-molecular glue targeting SARM1, as a potential disease-modifying therapy for ALS.
Asha's CSO Dr. Bradlee Heckmann will present efficacy data for ASHA-091 at the AD/PD 2024 conference, with plans to enter clinical trials in late 2024.